

The protective effects of astaxanthin against cisplatin-induced retinal toxicity

Hüseyin Fındık, Levent Tunkaya, Adnan Yılmaz, Mehmet Gökhan Aslan, Murat Okutucu, Kerimali Akyildizi & Tolga Mercantepe

To cite this article: Hüseyin Fındık, Levent Tunkaya, Adnan Yılmaz, Mehmet Gökhan Aslan, Murat Okutucu, Kerimali Akyildizi & Tolga Mercantepe (2018): The protective effects of astaxanthin against cisplatin-induced retinal toxicity, Cutaneous and Ocular Toxicology, DOI: [10.1080/15569527.2018.1518330](https://doi.org/10.1080/15569527.2018.1518330)

To link to this article: <https://doi.org/10.1080/15569527.2018.1518330>



Accepted author version posted online: 05 Sep 2018.



Submit your article to this journal [↗](#)



Article views: 1



View Crossmark data [↗](#)

The protective effects of astaxanthin against cisplatin-induced retinal toxicity

Running title: Astaxanthin against retinal toxicity

Hüseyin Fındık^a MD, Levent Tumkaya^b PhD, Adnan Yılmaz^c MD, Mehmet Gökhan Aslan^a
PhD, Murat OKUTUCU^a PhD, Kerimali AKYILDIZI^d Msc, Tolga Mercantepe^{b,*} PhD

^aDepartment of Ophthalmology, Faculty of Medicine, Recep Tayyip Erdogan University,
53100, Rize

^bDepartment of Histology and Embryology, Faculty of Medicine, Recep Tayyip Erdogan
University, 53100, Rize

^cDepartment of Biochemistry, Faculty of Medicine, Recep Tayyip Erdogan University, 53100,
Rize

^dDepartment of Medical Services and Techniques, Health Care Services Vocational School,
Recep Tayyip Erdogan University, 53100, Rize

***Corresponding Author:**

Tolga Mercantepe, Department of Histology and Embryology, Faculty of Medicine, Recep
Tayyip Erdoğan University, Islampaşa Mahallesi, İki numaralı Şehitler Caddesi, No: 74, Rize,
53010, Turkey. Telephone: (+90) 544 255 95 55. Fax: (+90) 464 212 30 15. E-
mail:tolgamercantepe@yahoo.com

Summary

This study investigated the toxic effects of an antineoplastic agent, Cisplatin (CIS), on retinal cells and the potential capacity of Astaxanthin (ASTA) to elicit a future therapeutic protocol in CIS-induced retinal toxicity. Six groups were formed for the assessment; control (healthy; Group 1), olive oil (olive oil only; Group 2), ASTA control group (ASTA only, Group 3), the single intraperitoneal (IP) dose of 16 mg/kg CIS (CIS only group; Group 4), 16 mg/kg CIS + 25 mg/kg (IP) ASTA (Group 5) and 16 mg/kg CIS + 75 mg/kg (IP) ASTA (Group 6). On the third day after cisplatin administration, rats in all groups were sacrificed under anesthesia and the analysis of the biochemical parameters and histopathological levels were performed. A significant decrease in GSH levels and increases in MDA, eNOS, 8-OHdG expressions were recorded. Additionally, CIS treatment had caused acidophilic staining in retinal histological appearance. ASTA treatment reduced the increases in MDA, eNOS, and 8-OHdG levels following CIS administration and increased the levels of GSH expressions, as well. These results may suggest the ASTA molecule as a promising option to prevent retinal toxicity in patients receiving CIS treatment for malignant tumors.

Keywords: Astaxanthin, chemotherapy, cisplatin toxicity, eNOS, oxidative stress, retina

Introduction

As an increasing health problem, cancer is a disease which causes multi-organ dysfunction and a major cause of death worldwide [1]. Several researchers point out the ascending pattern of numbers that may possibly affect the population in future and the results are devastating [2, 3]. Moreover, not only the disease itself, also the side effects of the therapy options are another issue to deal with through the way to recovery [4, 5].

Since its first approval as an antineoplastic in 1978, CIS is widely used to treat various cancer types such as head, neck, ovarian, testicular, breast and small cell lung [6]. Its side effects overhauling, kidneys, liver, and central nervous system were widely described in previous studies [7–10]. However, as a rare condition, its retinal toxicity is stated in a few case reports and the mechanism to explain this toxicity is yet to be cleared [11–13].

Oxidation and redox balance in accordance with a variety of enzymes is a vital feature of a human organism [14]. Reduced glutathione (GSH) which is a key element in this cycle has been described as an important molecule to follow up this balance [15]. A failure of antioxidant mechanisms leading to accumulation of reactive oxygen species is suggested to cause an activation of the proapoptotic process which is responsible for cell death and tissue damage [16]. Moreover, studies reporting the positive effect of antioxidant molecules such as selenium, vitamin E and fish oil against these toxicities, support this suggestion in explaining the probable mechanisms [17–19]. Mitochondrial and nuclear DNAs induced by reactive oxygen species show 8-hydroxy-2p-deoxyguanosine (8-OHdG) activation. Although the other components of the DNA interact with ROS as well, thanks to its easy forming pattern, 8-OHdG is the most common biomarker to observe the oxidative damage in cell structures [20, 21]. Malondialdehyde (MDA) is also known as a natural marker of lipid peroxidation and provides proof to determine the severity of tissue damage due to ROS [22, 23].

Astaxanthin (ASTA) is a member of carotenoids family and has been widely used in food industry as a pigment[24, 25]. The first description of ASTA was by Kuhn and Soerensen in 1937 and its effect on antioxidation processes was previously described in several studies in vivo and in vitro, as well [26–29]. Its potential antioxidative and neuroprotective effect was suggested as a therapy option for diabetes, cancer, and hepatotoxicity [30–33]. It is also used as a supplementary medication for dry type-age related macular degeneration patients[34].

This study aimed to assess the toxic effects of CIS on retinal cells and the protective effect of ASTA over this toxicity by investigating biochemical parameters and histopathological specimens. Even though there are few studies focused to discover molecules to reverse this toxicity, to the best of our knowledge, none of the previous studies investigated the effect of ASTA on this toxicity and neither described the histopathological damage zones caused by CIS.

Materials and Methods

Forty-eight male Sprague Dawley rats at the age of 13–15 weeks, and weighing 264.83 ± 7.39 g obtained from the Recep Tayyip Erdogan University Animal Care and Research Unit (Rize, Turkey) were used in this study. All rats received care according to the criteria outlined in the ‘Guide for the Care and Use of Laboratory Animals’ prepared by the National Academy of Sciences and published by the National Institutes of Health. Recep Tayyip Erdogan University (Rize, Turkey), Animal Ethical Committee approved this study.

Study Design

Animals were kept in Recep Tayyip Erdogan University Animal Care and Research Unit (Rize, Turkey). All animals were maintained and fed in the sterile experimental animal unit environment, having 55-60% humidity, the temperature of 22 ± 3 ° C, and 12-h light:12-h light-dark cycle. Rats were allowed access to commercially available standard rat chow (Bayramođlu Feed and Flour Industry Trading Corporation Erzurum, Turkey) and tap water ad libitum along the experiment. After sufficient time to comply with the laboratory conditions, 48 experimental animals were divided randomly into six groups.

Group 1 was the control group (n=8). No drugs were injected except for anesthetics. Group 2 acted as the olive oil control group (n=8). Olive oil was used for dissolving ASTA in groups 3-6. This group received intra-peritoneal olive oil only, for 8 days [35, 36]. Group 3 was the ASTA control group (n=8). This group received only intra-peritoneal ASTA 75mg/kg, dissolved in olive oil [37]. Group 4 acted as the CIS only group (n=8). 16mg/ kg single dose CIS (Cisplatin DBL 100mg / 100ml vial, Orna Ilac, İstanbul) was given IP on the 5th day [38]. Group 5 was formed by the 16 mg/kg CIS & 25mg/kg ASTA group (n=8). 25 mg/kg astaxanthin IP was given daily for 8 days, and 16 mg/kg single dose CIS was injected IP on the 5th day. Group 6 was determined to be the 16 mg/kg CIS & 75 mg/kg ASTA group (n=8). 75 mg/kg ASTA IP was given daily for eight days and 16 mg/kg single dose CIS was given IP on the 5th day (Figure 1). Rats in all groups were sacrificed under anesthesia on the third day after CIS administration. Anesthesia was performed to all groups with 50 mg/kg intraperitoneal Ketamine hydrochloride (Ketalar ®, Eczacibası Parke-Davis, Istanbul, Turkey) and 10 mg/kg intraperitoneal Xylazine HCl (Alfazyne ®, Alfasan International BV Woerden, Holland)[39].

Biochemical analysis

Glutathione (GSH) analysis

Eye tissues were prepared with Phosphate buffered saline (PBS; pH: 7.4). The samples were weighed and washed in ice-cold PBS. The GSH assessment was also performed according to the Beutler method[40, 41].

Malondialdehyde (MDA) analysis

The eye-tissue extract incubation was carried out with 900 μ L working tubes and 600 μ L of TCA solution was added and centrifuged at 3000 rpm for 10 minutes. MDA assessment was performed according to the Dormandy method [42].

Histopathological analysis procedure

The eye tissue specimens were fixed in 10% formalin (Merck, Darmstadt, Germany) for 36 hours and then paraffin embedded by routine histological follow-up protocol procedures. Eye tissue samples were divided into 3-4 μ m thick sections by the microtome and sections were stained with Harris hematoxylin and eosin G (H & E, (Merck, Darmstadt, Germany). Histopathological analysis was evaluated under a light microscope (Olympus BX51, Japan) with an Olympus DP20 (Olympus Corp, Japan) camera by two blind histopathologic examinations.

Immunohistochemistry (IHC) analysis procedure

2-3 μ m thick eye tissue sections were incubated with Anti-8 Hydroxyguanosine antibody (8 OH-dG, 1:200, Mouse monoclonal, Abcam, UK) and Anti-e-NOS antibody (1:100, Rabbit polyclonal, Abcam, UK). Then, eye tissue sections were incubated with a secondary antibody (Rabbit Specific HRP/DAB [ABC] Detection IHC kit, Abcam, UK). Thereafter, sections were incubated in anti-digoxigenin-peroxidase and were incubated with 0.06% 3, 3-

diaminobenzidine tetrahydrochloride (Sigma Chemical, St. Louis, MO). Eventually, eye sections were counterstained with Harris hematoxylin (Merck, Darmstadt, Germany).

Semi-quantitative analysis

The analysis was evaluated under x40 magnification under a light microscope (Olympus BX51, Japan) by two blinded histopathologists (LT with 10 years of experience and TM eight years of experience). Each IHC stained sections were randomly selected from 20 random areas for semi-quantitative analysis (Table 1)[35].

Quantitative analysis

The retinal thickness (μm) measurement for each eye tissue section in 20 different selected areas was performed with the Olympus DP2-BSW (Olympus Corporation, Tokyo, Japan) software system by two blinded histopathologists.

Statistical analysis

Data were analyzed using the SPSS Statistics 18.0 software (IBM Inc., Chicago, USA). Parametric variables were expressed as a mean \pm standard deviation. Parametric variables were tested by using the one-way analysis of variance (ANOVA) followed by the Tukey HSD test. Nonparametric the pars optical retinae thickness and semi-quantitative analysis variables were expressed as the median \pm standard deviation, and the differences between the groups were tested by using the Kruskal Wallis test; p values <0.05 were regarded as significant.

Results

Biochemical analysis

The mean MDA levels in the control group were 18.13 ± 1.57 mmol/L, rising to 24.01 ± 1.23 mmol/L in the CIS group ($P=0.000$; Table 2). ASTA 25 mg treatment reduced MDA levels after administration of CIS alone from 24.01 ± 1.23 mmol/L to 16.15 ± 0.66 mmol/L ($P=$

0.000; Figure 2; Table 2). ASTA 75 mg treatment reduced MDA levels after administration of CIS single dose from 24.01 ± 1.23 mmol/L to 15.93 ± 0.22 mmol/L ($P=0.000$; Table 2).

The mean GSH level in the control group was 24.40 ± 1.06 mmol/L and was reduced to 19.19 ± 1.11 mmol/L in the CIS group ($P=0.000$; Table 2). ASTA 25 mg treatment raised mean GSH level from 19.19 ± 1.11 mmol/L to 26.35 ± 1.30 after administration of CIS alone ($P=0.000$; Table 2). ASTA 75 mg treatment raised mean GSH level from 19.19 ± 1.11 mmol/L to 26.09 ± 1.38 after administration of Cis alone ($P=0.000$; Table 2).

Histopathological analysis

The normal histopathological characteristics of pars optica retinae were demonstrated (Figures 1A-B). Olive oil and only ASTA 75 mg group histopathological structures were similar to the control group (Figures 1C-E). Retinal cells in H&E stained sections from only CIS treatment group had more acidophilic stained histological appearance than the control group, but no sign of a pathology was observed (Figures 1F). In addition, retinal cells in ASTA 25 and 75 treatment groups, no sign of a pathology was observed.

Semi-quantitative analysis

We observed a larger number 8-OHdG positive staining particularly at the horizontal cells and other retinal neurons in the CIS group compared to the control group ($p=0.014$; Figure 2; Table 3). The ASTA 25 mg and ASTA 75 mg treated groups demonstrated less staining with 8-OHdG especially in horizontal cells and neurons than the CIS only group ($P=0.014$; $P=0.01$; respectively; Figure 2; Table 3).

A larger number of eNOS antibody staining was present in the retinal blood vessels in the CIS only group ($P=0.025$; Figure 3; Table 3). The ASTA 25 mg and ASTA 75 mg treatment decreased eNOS antibody staining positivity in the retinal blood vessels compared to cisplatin only group ($p=0.025$; Figure 3; Table 3).

Quantitative analysis

The pars optica retinae thickness measurements yielded significant differences in the CIS only group compared to the control group ($P=0.000$) (Table 4). On the other hand, ASTA 25 and 75 mg treatment reduced pars optica retinae thickness after administration of CIS ($P=0.016$, $p=0.03$; respectively, Table 4).

Discussion

In this animal study model, single dose IP CIS was administered to observe the toxic effects both histopathologically and biochemically. Sharp et. al. reported higher fibrotic marker levels after repeated doses of CIS [43]. Thus, this regimen was more likely to cause an interstitial fibrosis. Therefore, by a single-dose induction (16 mg/kg of CIS) we could obtain less destructed retinal specimens to assess CIS damage. Polat et. al reported retinal thickness increase and deterioration after single dose CIS administration which caused a thicker RPE in their specimens and presumed that RPE might be the most sensitive region to CIS toxicity [17]. Specimens in this study demonstrated an acidophilic staining with H&E dye which is an early indicator of tissue damage and a slight increase of retinal thickness was observed, as well. Moreover, we performed semi-quantitative analysis to the specimens for a more detailed assessment and observed significant 8-OHdG positive staining particularly in horizontal cells and other retinal neurons. Dulz et al. reported a significant decrease in RNFL thickness values of germ cell cancer patients receiving CIS based chemotherapy [12]. Furthermore, patients' full-field electroretinogram tests suggested mild changes at the cone photoreceptor level with significantly reduced and prolonged cone-b wave latency and a cone-a wave latency [12].

Nitric oxide takes part in basal blood flow of ocular tissues and is produced by three different nitric oxide synthase (NOS) according to the sight [44, 45]. Endothelial NOS (eNOS) is localized in choriocapillaris endothelium and significantly increases in endothelial

dysfunction. It is thought to have a role in ocular hemodynamic abnormalities which lead to various ocular disorders such as ischemic retinopathy and glaucoma [46]. In this study, the semi-quantitative analysis with eNOS staining of the specimens yielded larger numbers of stained retinal blood vessels. Kwan et al. reported a case of sudden vision loss due to CIS toxicity who had presented with widespread retinal cotton-wool spots, venous dilation, and microvascular abnormalities [11]. They presumed this toxicity as a vaso-occlusive process and the result of this study, significant eNOS staining of retinal vessels, might be a clear proof for their hypothesis.

As a potent antioxidant, ASTA decreases ROS formation and lipid peroxidation[47]. Lipid peroxidation was investigated by detecting tissue MDA levels in all groups and mean MDA level was significantly decreased in the CIS applied group. However, ASTA in either dose 25 mg/kg and 75 mg/kg for 8 days (in sum 200 mg/kg, 600 mg/kg, respectively) had decreased serum mean MDA value approximately to the mean level of the control group. Tong et al. investigated the effect of diosmin against ischemia-reperfusion injury in rat retina[23]. Retinal MDA level was significantly increased in the injured tissues and diosmin decreased MDA levels and was suggested to be protective against this injury [23]. Nakajima et al. administered 400 mg/kg AST in four doses which were estimated to reach at least 100 nM maximal serum concentrations [27]. They reported reduced ROS formation and less in-vitro retinal ganglion cell damage and claimed that even the ASTA concentrations as low as 10 nM could be effective [27]. GSH levels were assessed in both studies which investigate the effect of hesperidin and fish oil against CIS toxicity. Decreased GSH levels in only CIS treated groups and increased GSH levels after administration of antioxidant molecules were reported in these studies [17, 18]. Similarly, serum GSH values were assessed in this study to describe the oxidative damage and reduced GSH levels were observed in the CIS group.

Moreover, both ASTA doses increased GSH levels approximately to the mean level of the control group, which reflects the efficacy of ASTA against oxidation.

The anti-neoplastic effect of CIS was explained by DNA adducts formation, ROS accumulation, lipid peroxidation and mitochondrial stress increase [48]. Even though ASTA shows promise to diminish the toxic effects of CIS treatment, it was not determined in this study whether ASTA also diminishes anti-neoplastic activity. Further studies are necessary to investigate the effect of ASTA on the anti-neoplastic activity of CIS and to define proper doses which protect retinal tissues without sacrificing the main purpose of CIS therapy.

Funding

No conflicting relationship, proprietary or commercial interest in any material discussed in this article exists for any author.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Accepted Manuscript

References

1. Arteaga CL, Adamson PC, Engelman JA, et al. AACR Cancer Progress Report 2014. *Clin Cancer Res* 2014;20:SI-S112
2. Arteaga CL, Adamson PC, Engelman JA, et al. AACR Cancer Progress Report 2014. *Clin Cancer Res* 2014;20:S1–S112
3. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. *Adv Nutr* 2016;7:418–9
4. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. *Cancer* 2002;95:155–163
5. Vale C, Nightingale A, Spera N, Whelan A, Hanley B, Tierney JF. Late complications from chemoradiotherapy for cervical cancer: reflections from cervical cancer survivors 10 years after the national cancer institute alert. *Clin Oncol (R Coll Radiol)* 2010;22:588–9
6. Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. *J Nephrol* 2018;31:15–25
7. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. *Biomed Res Int* 2014;2014:967826
8. Mendonça LM, da Silva Machado C, Correia Teixeira CC, Pedro de Freitas LA, Pires Bianchi M de L, Greggi Antunes LM. Curcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cells. *Neurotoxicology* 2013;34:205–211
9. Cersosimo RJ. Hepatotoxicity Associated with Cisplatin Chemotherapy. *Ann*

Pharmacother 1993;27:438–441

10. Chirtes F, Albu S. Prevention and restoration of hearing loss associated with the use of cisplatin. *Biomed Res Int* 2014;2014:925485
11. Kwan ASL, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. *Am J Ophthalmol* 2006;141:196–197
12. Dulz S, Asselborn NH, Dieckmann K-P, et al. Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. *J Cancer Res Clin Oncol* 2017;143:1319–1325
13. Hilliard LM, Berkow RL, Watterson J, Ballard EA, Balzer GK, Moertel CL. Retinal Toxicity Associated With Cisplatin and Etoposide in Pediatric Patients. 1997;313:310–313
14. Owen JB, Butterfield DA. Measurement of Oxidized/Reduced Glutathione Ratio. 2010. Humana Press, Totowa, NJ, pp 269–277
15. Liu Y, Hyde AS, Simpson MA, Barycki JJ. Emerging regulatory paradigms in glutathione metabolism. *Adv Cancer Res* 2014;122:69–101
16. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. *Free Radic Biol Med* 2010;48:749–62
17. Polat N, Ciftci O, Cetin A, Yilmaz T. Toxic effects of systemic cisplatin on rat eyes and the protective effect of hesperidin against this toxicity. *Cutan Ocul Toxicol* 2016;35:1–7
18. Gul Baykalir B, Ciftci O, Cetin A, Basak Turkmen N. The protective effect of fish oil against cisplatin induced eye damage in rats. *Cutan Ocul Toxicol* 2017;0:1–6

19. Naziroğlu M, Karaoğlu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. *Toxicology* 2004;195:221–230
20. Wu L, Chiou C, Chang P, *acta JW-C chimica*, 2004 undefined. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Elsevier
21. Valavanidis A, ... *TV-J of environmental*, 2009 undefined. 8-hydroxy-2'-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. Taylor Fr
22. Chida M, Suzuki K, Nakanishi-Ueda T, et al. In vitro testing of antioxidants and biochemical end-points in bovine retinal tissue. *Ophthalmic Res* 1999;31:407–415
23. Tong N, Zhang Z, Gong Y, Yin L, Wu X. Diosmin Protects Rat Retina from Ischemia/Reperfusion Injury. *J Ocul Pharmacol Ther* 2012;28:459–466
24. Hashimoto H, Arai K, Hayashi S, et al. Effects of astaxanthin on antioxidation in human aqueous humor. *J Clin Biochem Nutr* 2013;53:1–7
25. Liu Po Hung AW et al. The astaxanthin-induced improvement in lipid metabolism during exercise is mediated by PGC-1 α increase in skeletal muscle. *J Clin Biochem Nutr* 2014;54:86–89
26. Chem RK-ZA, 1938 undefined. The coloring matters of the lobster (*Astacus gammarus* L.). *ci.nii.ac.jp*
27. Nakajima Y, Inokuchi Y, Shimazawa M, Otsubo K, Ishibashi T, Hara H. Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. *J Pharm Pharmacol* 2008;60:1365–1374

28. Kobayashi M. In vivo antioxidant role of astaxanthin under oxidative stress in the green alga *Haematococcus pluvialis*. *Appl Microbiol Biotechnol* 2000;54:550–5
29. Klinkenberg LJJ, Res PT, Haenen GR, et al. Effect of Antioxidant Supplementation on Exercise-Induced Cardiac Troponin Release in Cyclists: A Randomized Trial. *PLoS One* 2013;8:e79280
30. Kang JO, Kim SJ, Kim H. Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of CCl₄-treated rats. *Methods Find Exp Clin Pharmacol* 2001;23:79–84
31. Uchiyama K, Naito Y, Hasegawa G, Nakamura N, Takahashi J, Yoshikawa T. Astaxanthin protects β -cells against glucose toxicity in diabetic db/db mice. *Redox Rep* 2002;7:290–293
32. Jyonouchi H, Sun S, Iijima K, Gross MD. Antitumor Activity of Astaxanthin and Its Mode of Action. *Nutr Cancer* 2000;36:59–65
33. Ohgami K, Shiratori K, Kotake S, et al. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. *Invest Ophthalmol Vis Sci* 2003;44:2694–701
34. Piermarocchi S, Saviano S, Parisi V, et al. Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study. *Eur J Ophthalmol* 2012;22:216–25
35. Akca G, Eren H, Tumkaya L, et al. The protective effect of astaxanthin against cisplatin-induced nephrotoxicity in rats. *Biomed Pharmacother* 2018;100:575–582
36. Guo SX, Zhou HL, Huang CL, et al. Astaxanthin attenuates early acute kidney injury following severe burns in rats by ameliorating oxidative stress and mitochondrial-

- related apoptosis. *Mar Drugs* 2015;13:2105–2123
37. Turkez H, Geyikoglu F, Yousef MI. Beneficial effect of astaxanthin on 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced liver injury in rats. *Toxicol Ind Health* 2013;29:591–599
 38. Kim SH, Hong KO, Hwang JK, Park KK. Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice. *Food Chem Toxicol* 2005;43:117–122
 39. Sharp Patrick E.; La regina MC. The Laboratory RAT. In: Sharp Patrick E.; La regina MC (ed) Second. 2013. CRC Press Taylor& Francis, Baco Raton, Florida, p 7
 40. Beutler E. Glutathione in red blood cell metabolism. A manual of biochemical methods. In: Beutl (ed) 2nd ed. 1975. Grune and Stratton, New York, pp 112–114
 41. Sherman M. Weissman. Red Cell Metabolism. A Manual of Biochemical Methods. *Yale J Biol Med* 1976;49:310–311
 42. Dormandy TL. The autoxidation of human red cell lipids induced by hydrogen peroxide. *Br J Haematol* 1971;20:95–110
 43. Sharp CN, Doll MA, Dupre T V, et al. Repeated administration of low-dose cisplatin in mice induces fibrosis. *Am J Physiol Renal Physiol* 2016;310:F560-8
 44. Moncada S. Nitric oxide: discovery and impact on clinical medicine. *J R Soc Med* 1999;92:164–9
 45. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 1991;43:109–42
 46. Giove TJ, Deshpande MM, Eldred WD. Identification of alternate transcripts of

neuronal nitric oxide synthase in the mouse retina. *J Neurosci Res* 2009;87:3134–42

47. Shimidzu N, Goto M, Miki W. Carotenoids as Singlet Oxygen Quenchers in Marine Organisms. *Fish Sci* 1996;62:134–137

48. Amin A, Buratovich MA. New platinum and ruthenium complexes--the latest class of potential chemotherapeutic drugs--a review of recent developments in the field. *Mini Rev Med Chem* 2009;9:1489–503

Table 1. IHC Staining Positivity Score.

Grading of the IHC Staining Positivity Score	
0	None
1	Mild (less than 5%)
2	Moderate (involvement 5%-25%)
3	Severe (more than %25)

Table 2. Mean \pm SD and statistical evaluations of MDA and GSH values.

Groups	MDA (mmol/L)	GSH (mmol/L)
Control	18.13 \pm 1.57**	24.40 \pm 1.06**
Olive oil	17.77 \pm 1.02**	25.14 \pm 0.87**
Asta 75mg	14.71 \pm 1.02**	28.94 \pm 0.61**
Cisplatin	24.01 \pm 1.23*	19.19 \pm 1.11*
Cisplatin+asta 25mg	16.15 \pm 0.66**	26.35 \pm 1.30**
Cisplatin+asta 75mg	15.93 \pm 0.22**	26.09 \pm 1.38**

* p<0.05 versus to control group.

** p<0.05 versus to Cisplatin group.

Tukey Test

Table 3. Semi-quantitative analysis data (Median \pm SD).

Groups	8-OHdG Positivity score	eNOS positivity score
Control	0.00 \pm 0.41	0.00 \pm 0.41
Olive oil	0.00 \pm 0.41 [#]	0.00 \pm 0.41 [#]
Asta 75mg	0.00 \pm 0.41 [#]	0.00 \pm 0.41 [#]
Cisplatin	1.50 \pm 0.55*	1.00 \pm 0.52*
Cisplatin+asta 25mg	0.0 \pm 0.41 [#]	0.00 \pm 0.41 [#]
Cisplatin+asta 75mg	0.00 \pm 0.41 [#]	0.00 \pm 0.41 [#]

* p<0.05 versus to Control group.

[#] p<0.05 versus to Cisplatin group.

Kruskal Wallis; Tamhane Test

Table 4. Median \pm SD and statistical evaluations of Retinal thickness (μm).

Groups	Retinal thickness (μm)
Control	105.00 \pm 9.27
Olive oil	112.57 \pm 14.58 [#]
Asta 75mg	99.16 \pm 4.41 [#]
Cisplatin	133.47 \pm 6.27 [*]
Cisplatin+Asta 25mg	110.85 \pm 17.23 [#]
Cisplatin+Asta 75mg	102.17 \pm 24.50 [#]

* p<0.05 versus to Control group.
p<0.05 versus to Cisplatin group.
Kruskal Wallis Test

Figure 1. Representative light microscopic photographs from pars optica retinae stained with H&E.

Photosensitive Layer (PL). Outer limiting membrane (OLM), Outer nuclear layer (ONL). Outer plexiform layer (OPL). Inner nuclear layer (INL). Inner plexiform layer (IPL). Ganglion cell layer (GCL). Inner limiting membrane (ILM).








A (x400)-B(x400): Control Group; Healthy pars optica retinae layer image of the control group. **C (x400)-D (x600): Olive oil Group;** Pars optica retinae of the regular structure is observed. **E (x400): Astaxanthin 75 mg Group;** Pars optica retinae are observed to be in the normal structure. **F(x600): Cisplatin Group;** Cisplatin treatment acidophilic staining histological appearance. **G (x600): Cisplatin+Astaxanthin 25 mg Group;** Astaxanthin 25 mg treatment no pathology was observed. **H (x400): Cisplatin+Astaxanthin 75 mg Group;** Glomerulus in regular structure (gl). Figure demonstrated that the proximal (pt) and distal tubules (dt) are in a stranded structure.







Figure 2. Representative light microscopic photographs from pars optica retinae stained with 8-OHdG.

A(x200) Control Group. B (x400): Olive oil Group; None 8-OHdG immunoreactivity were observed **C(x600): Astaxanthin 75 mg Group;** None 8-OHdG expression observed. **D (x400): Cisplatin Group;** 8-OHdG positive immunoreactivity were observed (arrow) ($p=0.014$; $p<0.05$). **E (x600): Cisplatin+Astaxanthin 25 mg Group;** Astaxanthin 25 mg treatment no immunoreactivity was observed ($p=0.014$; $p<0.05$) **F (x600): Cisplatin+Astaxanthin 75 mg Group;** No immunoreactivity was observed ($p=0.01$; $p<0.05$).


Figure 3. Representative light microscopic photographs from pars optica retinae stained with eNOS.

A(x200) Control Group. B (x400): Olive oil Group; None eNOS immunoreactivity were observed. **C(x600): Astaxanthin 75 mg Group;** No immunoreactivity observed. **D (x400): Cisplatin Group;** Cisplatin treatment eNOS positive immunoreactivity (arrow) were observed ($p=0.025$; $p<0.05$). **E (x600): Cisplatin+Astaxanthin 25 mg Group;** Astaxanthin 25 mg treatment no immunoreactivity was observed ($p=0.025$; $p<0.05$). **F (x600): Cisplatin+Astaxanthin 75 mg Group;** No immunoreactivity was observed ($p=0.025$; $p<0.05$).





Accepted Manuscript



Accepted Manuscript